Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

Also called NCT03153137

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
  • Actelion Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03153137
  • EudraCT 2016-003320-23
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, China, Czechia, Denmark, France, Germany, New Zealand, Poland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03153137. Randomized; quadruple masking; primary purpose treatment. Start 2017-08-14 (actual); primary completion 2021-06-30 (actual). Results posted on 2022-09-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
Acronym
RUBATO
Condition
Congenital Heart Disease
Intervention (Drug)
Macitentan 10 mg
Intervention (Drug)
Placebo
Lead sponsor
Actelion (class: industry)

Record details

Record id
cardio:ct-nct03153137
Content hash
cf6c166901925285ae73bf14d7b8d22f034085ee7c0122cdf403726ab147f274